Global Refractory Multiple Myeloma Market Growth (Status and Outlook) 2023-2029

August 2023 | 101 pages | ID: GD8E3E2ABA2DEN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our (LP Info Research) latest study, the global Refractory Multiple Myeloma market size was valued at US$ million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Refractory Multiple Myeloma is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.

The research report highlights the growth potential of the global Refractory Multiple Myeloma market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Refractory Multiple Myeloma are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Refractory Multiple Myeloma. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Refractory Multiple Myeloma market.

Key Features:

The report on Refractory Multiple Myeloma market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Refractory Multiple Myeloma market. It may include historical data, market segmentation by Type (e.g., Proteosome Inhibitor, Immunomodulators), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Refractory Multiple Myeloma market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Refractory Multiple Myeloma market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Refractory Multiple Myeloma industry. This include advancements in Refractory Multiple Myeloma technology, Refractory Multiple Myeloma new entrants, Refractory Multiple Myeloma new investment, and other innovations that are shaping the future of Refractory Multiple Myeloma.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Refractory Multiple Myeloma market. It includes factors influencing customer ' purchasing decisions, preferences for Refractory Multiple Myeloma product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Refractory Multiple Myeloma market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Refractory Multiple Myeloma market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Refractory Multiple Myeloma market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Refractory Multiple Myeloma industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Refractory Multiple Myeloma market.

Market Segmentation:

Refractory Multiple Myeloma market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Segmentation by type

• Proteosome Inhibitor
• Immunomodulators
• Anti-CD38 Monoclonal Antibody
• Others

Segmentation by application

• Hospital
• Specialty Clinic
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Bristol Myers Squibb
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Janssen Global Services, LLC
• Gilead Sciences, Inc.
• Fresenius Kabi
• GSK plc.
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Genentech, Inc.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Refractory Multiple Myeloma Market Size 2018-2029
  2.1.2 Refractory Multiple Myeloma Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Refractory Multiple Myeloma Segment by Type
  2.2.1 Proteosome Inhibitor
  2.2.2 Immunomodulators
  2.2.3 Anti-CD38 Monoclonal Antibody
  2.2.4 Others
2.3 Refractory Multiple Myeloma Market Size by Type
  2.3.1 Refractory Multiple Myeloma Market Size CAGR by Type (2018 VS 2022 VS 2029)
  2.3.2 Global Refractory Multiple Myeloma Market Size Market Share by Type (2018-2023)
2.4 Refractory Multiple Myeloma Segment by Application
  2.4.1 Hospital
  2.4.2 Specialty Clinic
  2.4.3 Others
2.5 Refractory Multiple Myeloma Market Size by Application
  2.5.1 Refractory Multiple Myeloma Market Size CAGR by Application (2018 VS 2022 VS 2029)
  2.5.2 Global Refractory Multiple Myeloma Market Size Market Share by Application (2018-2023)

3 REFRACTORY MULTIPLE MYELOMA MARKET SIZE BY PLAYER

3.1 Refractory Multiple Myeloma Market Size Market Share by Players
  3.1.1 Global Refractory Multiple Myeloma Revenue by Players (2018-2023)
  3.1.2 Global Refractory Multiple Myeloma Revenue Market Share by Players (2018-2023)
3.2 Global Refractory Multiple Myeloma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 REFRACTORY MULTIPLE MYELOMA BY REGIONS

4.1 Refractory Multiple Myeloma Market Size by Regions (2018-2023)
4.2 Americas Refractory Multiple Myeloma Market Size Growth (2018-2023)
4.3 APAC Refractory Multiple Myeloma Market Size Growth (2018-2023)
4.4 Europe Refractory Multiple Myeloma Market Size Growth (2018-2023)
4.5 Middle East & Africa Refractory Multiple Myeloma Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas Refractory Multiple Myeloma Market Size by Country (2018-2023)
5.2 Americas Refractory Multiple Myeloma Market Size by Type (2018-2023)
5.3 Americas Refractory Multiple Myeloma Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Refractory Multiple Myeloma Market Size by Region (2018-2023)
6.2 APAC Refractory Multiple Myeloma Market Size by Type (2018-2023)
6.3 APAC Refractory Multiple Myeloma Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Refractory Multiple Myeloma by Country (2018-2023)
7.2 Europe Refractory Multiple Myeloma Market Size by Type (2018-2023)
7.3 Europe Refractory Multiple Myeloma Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Refractory Multiple Myeloma by Region (2018-2023)
8.2 Middle East & Africa Refractory Multiple Myeloma Market Size by Type (2018-2023)
8.3 Middle East & Africa Refractory Multiple Myeloma Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL REFRACTORY MULTIPLE MYELOMA MARKET FORECAST

10.1 Global Refractory Multiple Myeloma Forecast by Regions (2024-2029)
  10.1.1 Global Refractory Multiple Myeloma Forecast by Regions (2024-2029)
  10.1.2 Americas Refractory Multiple Myeloma Forecast
  10.1.3 APAC Refractory Multiple Myeloma Forecast
  10.1.4 Europe Refractory Multiple Myeloma Forecast
  10.1.5 Middle East & Africa Refractory Multiple Myeloma Forecast
10.2 Americas Refractory Multiple Myeloma Forecast by Country (2024-2029)
  10.2.1 United States Refractory Multiple Myeloma Market Forecast
  10.2.2 Canada Refractory Multiple Myeloma Market Forecast
  10.2.3 Mexico Refractory Multiple Myeloma Market Forecast
  10.2.4 Brazil Refractory Multiple Myeloma Market Forecast
10.3 APAC Refractory Multiple Myeloma Forecast by Region (2024-2029)
  10.3.1 China Refractory Multiple Myeloma Market Forecast
  10.3.2 Japan Refractory Multiple Myeloma Market Forecast
  10.3.3 Korea Refractory Multiple Myeloma Market Forecast
  10.3.4 Southeast Asia Refractory Multiple Myeloma Market Forecast
  10.3.5 India Refractory Multiple Myeloma Market Forecast
  10.3.6 Australia Refractory Multiple Myeloma Market Forecast
10.4 Europe Refractory Multiple Myeloma Forecast by Country (2024-2029)
  10.4.1 Germany Refractory Multiple Myeloma Market Forecast
  10.4.2 France Refractory Multiple Myeloma Market Forecast
  10.4.3 UK Refractory Multiple Myeloma Market Forecast
  10.4.4 Italy Refractory Multiple Myeloma Market Forecast
  10.4.5 Russia Refractory Multiple Myeloma Market Forecast
10.5 Middle East & Africa Refractory Multiple Myeloma Forecast by Region (2024-2029)
  10.5.1 Egypt Refractory Multiple Myeloma Market Forecast
  10.5.2 South Africa Refractory Multiple Myeloma Market Forecast
  10.5.3 Israel Refractory Multiple Myeloma Market Forecast
  10.5.4 Turkey Refractory Multiple Myeloma Market Forecast
  10.5.5 GCC Countries Refractory Multiple Myeloma Market Forecast
10.6 Global Refractory Multiple Myeloma Forecast by Type (2024-2029)
10.7 Global Refractory Multiple Myeloma Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 Bristol Myers Squibb
  11.1.1 Bristol Myers Squibb Company Information
  11.1.2 Bristol Myers Squibb Refractory Multiple Myeloma Product Offered
  11.1.3 Bristol Myers Squibb Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.1.4 Bristol Myers Squibb Main Business Overview
  11.1.5 Bristol Myers Squibb Latest Developments
11.2 Teva Pharmaceutical Industries Ltd.
  11.2.1 Teva Pharmaceutical Industries Ltd. Company Information
  11.2.2 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product Offered
  11.2.3 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.2.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
  11.2.5 Teva Pharmaceutical Industries Ltd. Latest Developments
11.3 Pfizer Inc.
  11.3.1 Pfizer Inc. Company Information
  11.3.2 Pfizer Inc. Refractory Multiple Myeloma Product Offered
  11.3.3 Pfizer Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.3.4 Pfizer Inc. Main Business Overview
  11.3.5 Pfizer Inc. Latest Developments
11.4 Janssen Global Services, LLC
  11.4.1 Janssen Global Services, LLC Company Information
  11.4.2 Janssen Global Services, LLC Refractory Multiple Myeloma Product Offered
  11.4.3 Janssen Global Services, LLC Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.4.4 Janssen Global Services, LLC Main Business Overview
  11.4.5 Janssen Global Services, LLC Latest Developments
11.5 Gilead Sciences, Inc.
  11.5.1 Gilead Sciences, Inc. Company Information
  11.5.2 Gilead Sciences, Inc. Refractory Multiple Myeloma Product Offered
  11.5.3 Gilead Sciences, Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.5.4 Gilead Sciences, Inc. Main Business Overview
  11.5.5 Gilead Sciences, Inc. Latest Developments
11.6 Fresenius Kabi
  11.6.1 Fresenius Kabi Company Information
  11.6.2 Fresenius Kabi Refractory Multiple Myeloma Product Offered
  11.6.3 Fresenius Kabi Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.6.4 Fresenius Kabi Main Business Overview
  11.6.5 Fresenius Kabi Latest Developments
11.7 GSK plc.
  11.7.1 GSK plc. Company Information
  11.7.2 GSK plc. Refractory Multiple Myeloma Product Offered
  11.7.3 GSK plc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.7.4 GSK plc. Main Business Overview
  11.7.5 GSK plc. Latest Developments
11.8 Novartis AG
  11.8.1 Novartis AG Company Information
  11.8.2 Novartis AG Refractory Multiple Myeloma Product Offered
  11.8.3 Novartis AG Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.8.4 Novartis AG Main Business Overview
  11.8.5 Novartis AG Latest Developments
11.9 Takeda Pharmaceutical Company Limited
  11.9.1 Takeda Pharmaceutical Company Limited Company Information
  11.9.2 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product Offered
  11.9.3 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.9.4 Takeda Pharmaceutical Company Limited Main Business Overview
  11.9.5 Takeda Pharmaceutical Company Limited Latest Developments
11.10 Genentech, Inc.
  11.10.1 Genentech, Inc. Company Information
  11.10.2 Genentech, Inc. Refractory Multiple Myeloma Product Offered
  11.10.3 Genentech, Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  11.10.4 Genentech, Inc. Main Business Overview
  11.10.5 Genentech, Inc. Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Refractory Multiple Myeloma Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Proteosome Inhibitor
Table 3. Major Players of Immunomodulators
Table 4. Major Players of Anti-CD38 Monoclonal Antibody
Table 5. Major Players of Others
Table 6. Refractory Multiple Myeloma Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 7. Global Refractory Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 8. Global Refractory Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 9. Refractory Multiple Myeloma Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 10. Global Refractory Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 11. Global Refractory Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 12. Global Refractory Multiple Myeloma Revenue by Players (2018-2023) & ($ Millions)
Table 13. Global Refractory Multiple Myeloma Revenue Market Share by Player (2018-2023)
Table 14. Refractory Multiple Myeloma Key Players Head office and Products Offered
Table 15. Refractory Multiple Myeloma Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Refractory Multiple Myeloma Market Size by Regions 2018-2023 & ($ Millions)
Table 19. Global Refractory Multiple Myeloma Market Size Market Share by Regions (2018-2023)
Table 20. Global Refractory Multiple Myeloma Revenue by Country/Region (2018-2023) & ($ millions)
Table 21. Global Refractory Multiple Myeloma Revenue Market Share by Country/Region (2018-2023)
Table 22. Americas Refractory Multiple Myeloma Market Size by Country (2018-2023) & ($ Millions)
Table 23. Americas Refractory Multiple Myeloma Market Size Market Share by Country (2018-2023)
Table 24. Americas Refractory Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 25. Americas Refractory Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 26. Americas Refractory Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 27. Americas Refractory Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 28. APAC Refractory Multiple Myeloma Market Size by Region (2018-2023) & ($ Millions)
Table 29. APAC Refractory Multiple Myeloma Market Size Market Share by Region (2018-2023)
Table 30. APAC Refractory Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 31. APAC Refractory Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 32. APAC Refractory Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 33. APAC Refractory Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 34. Europe Refractory Multiple Myeloma Market Size by Country (2018-2023) & ($ Millions)
Table 35. Europe Refractory Multiple Myeloma Market Size Market Share by Country (2018-2023)
Table 36. Europe Refractory Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 37. Europe Refractory Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 38. Europe Refractory Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 39. Europe Refractory Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 40. Middle East & Africa Refractory Multiple Myeloma Market Size by Region (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Refractory Multiple Myeloma Market Size Market Share by Region (2018-2023)
Table 42. Middle East & Africa Refractory Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Refractory Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 44. Middle East & Africa Refractory Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 45. Middle East & Africa Refractory Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 46. Key Market Drivers & Growth Opportunities of Refractory Multiple Myeloma
Table 47. Key Market Challenges & Risks of Refractory Multiple Myeloma
Table 48. Key Industry Trends of Refractory Multiple Myeloma
Table 49. Global Refractory Multiple Myeloma Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 50. Global Refractory Multiple Myeloma Market Size Market Share Forecast by Regions (2024-2029)
Table 51. Global Refractory Multiple Myeloma Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 52. Global Refractory Multiple Myeloma Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 53. Bristol Myers Squibb Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 54. Bristol Myers Squibb Refractory Multiple Myeloma Product Offered
Table 55. Bristol Myers Squibb Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 56. Bristol Myers Squibb Main Business
Table 57. Bristol Myers Squibb Latest Developments
Table 58. Teva Pharmaceutical Industries Ltd. Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 59. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product Offered
Table 60. Teva Pharmaceutical Industries Ltd. Main Business
Table 61. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 62. Teva Pharmaceutical Industries Ltd. Latest Developments
Table 63. Pfizer Inc. Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 64. Pfizer Inc. Refractory Multiple Myeloma Product Offered
Table 65. Pfizer Inc. Main Business
Table 66. Pfizer Inc. Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 67. Pfizer Inc. Latest Developments
Table 68. Janssen Global Services, LLC Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 69. Janssen Global Services, LLC Refractory Multiple Myeloma Product Offered
Table 70. Janssen Global Services, LLC Main Business
Table 71. Janssen Global Services, LLC Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 72. Janssen Global Services, LLC Latest Developments
Table 73. Gilead Sciences, Inc. Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 74. Gilead Sciences, Inc. Refractory Multiple Myeloma Product Offered
Table 75. Gilead Sciences, Inc. Main Business
Table 76. Gilead Sciences, Inc. Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 77. Gilead Sciences, Inc. Latest Developments
Table 78. Fresenius Kabi Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 79. Fresenius Kabi Refractory Multiple Myeloma Product Offered
Table 80. Fresenius Kabi Main Business
Table 81. Fresenius Kabi Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 82. Fresenius Kabi Latest Developments
Table 83. GSK plc. Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 84. GSK plc. Refractory Multiple Myeloma Product Offered
Table 85. GSK plc. Main Business
Table 86. GSK plc. Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 87. GSK plc. Latest Developments
Table 88. Novartis AG Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 89. Novartis AG Refractory Multiple Myeloma Product Offered
Table 90. Novartis AG Main Business
Table 91. Novartis AG Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 92. Novartis AG Latest Developments
Table 93. Takeda Pharmaceutical Company Limited Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 94. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product Offered
Table 95. Takeda Pharmaceutical Company Limited Main Business
Table 96. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 97. Takeda Pharmaceutical Company Limited Latest Developments
Table 98. Genentech, Inc. Details, Company Type, Refractory Multiple Myeloma Area Served and Its Competitors
Table 99. Genentech, Inc. Refractory Multiple Myeloma Product Offered
Table 100. Genentech, Inc. Main Business
Table 101. Genentech, Inc. Refractory Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 102. Genentech, Inc. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Refractory Multiple Myeloma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Refractory Multiple Myeloma Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Refractory Multiple Myeloma Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Refractory Multiple Myeloma Sales Market Share by Country/Region (2022)
Figure 8. Refractory Multiple Myeloma Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Refractory Multiple Myeloma Market Size Market Share by Type in 2022
Figure 10. Refractory Multiple Myeloma in Hospital
Figure 11. Global Refractory Multiple Myeloma Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Refractory Multiple Myeloma in Specialty Clinic
Figure 13. Global Refractory Multiple Myeloma Market: Specialty Clinic (2018-2023) & ($ Millions)
Figure 14. Refractory Multiple Myeloma in Others
Figure 15. Global Refractory Multiple Myeloma Market: Others (2018-2023) & ($ Millions)
Figure 16. Global Refractory Multiple Myeloma Market Size Market Share by Application in 2022
Figure 17. Global Refractory Multiple Myeloma Revenue Market Share by Player in 2022
Figure 18. Global Refractory Multiple Myeloma Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Refractory Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 20. APAC Refractory Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 21. Europe Refractory Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Refractory Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 23. Americas Refractory Multiple Myeloma Value Market Share by Country in 2022
Figure 24. United States Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Refractory Multiple Myeloma Market Size Market Share by Region in 2022
Figure 29. APAC Refractory Multiple Myeloma Market Size Market Share by Type in 2022
Figure 30. APAC Refractory Multiple Myeloma Market Size Market Share by Application in 2022
Figure 31. China Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Refractory Multiple Myeloma Market Size Market Share by Country in 2022
Figure 38. Europe Refractory Multiple Myeloma Market Size Market Share by Type (2018-2023)
Figure 39. Europe Refractory Multiple Myeloma Market Size Market Share by Application (2018-2023)
Figure 40. Germany Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Refractory Multiple Myeloma Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Refractory Multiple Myeloma Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Refractory Multiple Myeloma Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Refractory Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 54. APAC Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 55. Europe Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 57. United States Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 58. Canada Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 61. China Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 62. Japan Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 63. Korea Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 65. India Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 66. Australia Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 67. Germany Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 68. France Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 69. UK Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 70. Italy Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 71. Russia Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 72. Spain Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 75. Israel Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Refractory Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 78. Global Refractory Multiple Myeloma Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Refractory Multiple Myeloma Market Size Market Share Forecast by Application (2024-2029)